Skip to main content
. 2024 Mar 4;12(3):326–338. doi: 10.1002/ueg2.12542

TABLE 3.

Association between demographic and clinical characteristics and risk of moderately severe or severe acute pancreatitis.

Mild pancreatitis Moderately severe/Severe pancreatitis p‐value
Sex, n (%) 0.001
Male 686 (48) 199 (58)
Female 740 (52) 143 (42)
Median age, years (IQR) 56 (41–72) 56.5 (41–73) 0.642
Age category, n (%) 0.624
<30 123 (9) 31 (9)
30–40 196 (14) 42 (12)
40–50 217 (15) 53 (15)
50–60 272 (19) 67 (20)
60–70 213 (15) 50 (15)
70–80 220 (15) 43 (13)
>80 185 (13) 56 (16)
Ethnicity <0.001
Asian 217 (16) 95 (28)
Black 31 (2) 14 (4)
Caucasian 1033 (74) 217 (65)
Other 111 (8) 10 (3)
Aetiology, n (%) a
Biliary 851 (60) 190 (56) 0.164
Alcohol 238 (17) 94 (27) <0.001
Post ERCP 47 (3) 12 (4) 0.867
Hypertriglyceridemia 42 (3) 14 (4) 0.301
Other 293 (21) 52 (15) 0.027
Predicted severity at admission, n (%) <0.001
Mild AP 923 (85) 145 (51)
Severe AP 164 (15) 137 (49)
Median CCI‐score (IQR) 1 (0–4) 2 (0–4) 0.005
CCI Category, n (%) 0.016
0 481 (35) 101 (30)
1–2 411 (29) 85 (26)
>2 496 (36) 148 (44)
Median pain severity at admission, NRS (IQR) 7 (5–8) 8 (6–9) <0.001
Pain duration prior to admission, n (%) <0.001
<12 h 397 (28) 70 (21)
12–24 h 415 (30) 83 (24)
>24 h 592 (42) 186 (55)
Timing of opioid treatment, n (%) <0.001
No opioids given during admission 486 (34) 79 (23)
Administered on admission day 819 (57) 217 (64)
Administered after admission day 121 (9) 46 (13)
Opioid administered during admission, n (%) <0.001
No opioids 486 (34) 79 (23)
Weak opioids 239 (17) 75 (22)
Strong opioids 701 (49) 188 (55)
Median duration of opioid treatment, days (IQR) 2 (0–4) 3 (1–7) <0.001
a

A subset of patients had overlapping aetiological risk factors. Continuous variables were tested using Student's t‐test or Wilcoxon Rank Sum test, depending on normality. Categorical variables were tested using Chi‐squared test or Fischer's exact test in case of low numbers.